 |
|
COMMENTS AND OPINIONS
Oral Sodium Phosphate Drug Products and Renal Function
Kevin C. Abbott, MD, MPH;
Erin M. Bohen, MD;
Frank P. Hurst, MD
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Oral phosphosoda (OSP) is currently the dominant bowel purgative in the United States. However, recent appreciation of the syndrome of acute phosphate nephropathy and its possible association with the use of OSP have raised potential concerns about the risk-benefit balance of OSP use for bowel preparation. The recent article by Khurana et al1 adds important information to this controversy because it is one of the few population-based studies in which OSP use has been associated with a statistically significant alteration in kidney function. Because the accompanying editorial called for larger studies that included polyethylene glycol (PEG) control groups,2 we would like to call attention to 3 recently published studies that fulfill those criteria. Furthermore, as authors of one of those studies, we would like to share additional findings that were not reported in our original study that . . . [Full Text of this Article]
AUTHOR INFORMATION
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Purging the Colon While Preserving the Kidneys
Hemant K. Roy and Laura K. Bianchi
Arch Intern Med. 2008;168(6):565-567.
EXTRACT
| FULL TEXT
The Effect of Oral Sodium Phosphate Drug Products on Renal Function in Adults Undergoing Bowel Endoscopy
Anand Khurana, Luciana McLean, Sheree Atkinson, and Charles J. Foulks
Arch Intern Med. 2008;168(6):593-597.
ABSTRACT
| FULL TEXT
|
